Albatira, Myline T.

HRN: 21-24-71  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/18/2022
CEFUROXIME 750MG (VIAL)
05/18/2022
05/20/2022
IVT
750mg 6 Doses
Q8
S/P Cesarean Section
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft TissueReproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: No  Wrong Dose  Wrong Dose

Overall appropriateness: No  Optimize Dose

Intervention



Type of Intervention done:

                    

           


Acceptance: